Second-generation antipsychotic drug use in hospital inpatients with dementia: The impact of a safety warning on rates of prescribing

Journal of Public Health (United Kingdom)

Volumn 37, Issue 2, 2015, Pages 346-352

  McIlroy, Graham ^a   Thomas, Sarah K ^a,b   Coleman, Jamie J ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

mental health

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

CLINICAL PRACTICE; DEMENTIA; ENGLAND; FEMALE; HOSPITAL PATIENT; HUMAN; MALE; STATISTICS AND NUMERICAL DATA;

ANTIPSYCHOTIC AGENTS; DEMENTIA; ENGLAND; FEMALE; HUMANS; INPATIENTS; MALE; PRACTICE PATTERNS, PHYSICIANS'; RISPERIDONE;

EID: 84930725888     PISSN: 17413842     EISSN: 17413850     Source Type: Journal    
DOI: 10.1093/pubmed/fdu023     Document Type: Article

References (33)

1. Lakey L, Chandaria K, Quince C et al. Dementia 2012: A National Challenge. London: Alzheimer's Society, 2012.
2. Sampson EL, Blanchard MR, Jones L et al. Dementia in the acute hospital: prospective cohort study of prevalence and mortality. Br J Psychiatry 2009;195(1):61-6.
3. Harwood RH. Dementia for hospital physicians. Clin Med 2012;12(1):35-9.
4. Ballard C, Day S, Sharp S et al. Neuropsychiatric symptoms in dementia: importance and treatment considerations. Int Rev Psychiatry 2008;20(4):396-404.
5. Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: The Cache County Study. Int J Geriatr Psychiatry 2008;23(2):170-7.
6. Ballard C, Corbett A, Chitramohan R et al. Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions. Curr Opin Psychiatry 2009;22(6):532-40.
7. Barton R, Hurst L. Unnecessary use of tranquilizers in elderly patients. Br J Psychiatry 1966;112(491):989-90.
8. Shah SM, Carey IM, Harris T et al. Antipsychotic prescribing to older people living in care homes and the community in England and Wales. Int J Geriatr Psychiatry 2011;26(4):423-34.
9. Alldred A, Petty D, Bowie P et al. Antipsychotic prescribing patterns in care homes and relationship with dementia. Psychiatric Bull 2007;31:329-32.
10. Rapoport M, Mamdani M, Shulman KI et al. Antipsychotic use in the elderly: shifting trends and increasing costs. Int J Geriatr Psychiatry 2005;20(8):749-53.
11. Lövheim H, Sandman PO, Karlsson S et al. Changes between 1982 and 2000 in the prevalence of behavioral symptoms and psychotropic drug treatment among old people with cognitive impairment in geriatric care. Int Psychogeriatr 2009;21(5):941-8.
12. Lövheim H, Gustafson Y, Karlsson S et al. Comparison of behavioral and psychological symptoms of dementia and psychotropic drug treatments among old people in geriatric care in 2000 and 2007. Int Psychogeriatr 2011;23(10):1616-22.
13. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14(3):191-210.
14. Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006;(1):Art. No.: CD003476. DOI: 10.1002/14651858.CD003476.pub2.
15. Yury CA, Fisher JE. Meta-analysis of the effectiveness of atypical antipsychotics for the treatment of behavioural problems in persons with dementia. Psychother Psychosom 2007;76(4):213-8.
16. Mittal V, Kurup L, Williamson D et al. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: A literature review of evidence. Am J Alzheimers Dis Other Demen 2011;26(1):10-28.
17. Sacchetti E, Turrina C, Valsecchi P. Cerebrovascular accidents in elderly people treated with antipsychotic drugs: A systematic review. Drug Saf 2010;33(4):273-88.
18. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294(15):1934-43.
19. Schneider LS, Tariot PN, Dagerman KS et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355(15):1525-38.
20. CSM. Atypical antipsychotic drugs and stroke. http://www.mhra.gov. uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarning sandmessagesformedicines/CON10042982004 (5 May 2012, date last accessed).
21. FDA. Public health advisory: Deaths with antipsychotics in elderly patients with behavioural disturbances. http://www.fda.gov/for consumers/consumerupdates/ucm053171.htm2005 (5 May 2012, date last accessed).
22. CHMP. Opinion following an article 30 referral for Risperdal and associated names. European Medicines Agency, Doc. Ref. EMEA/ CHMP/384877/2008. 2008.
23. MHRA. Antipsychotics: use in elderly people with dementia. MHRA Drug Safety Update 2009; 2(8). 2009.
24. Wagner AK, Soumerai SB, Zhang F et al. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther 2002;27(4):299-309.
25. Kales HC, Zivin K, Kim HM et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry 2011;68(2):190-7.
26. Valiyeva E, Herrmann N, Rochon PA et al. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: A population-based time-series analysis. CMAJ 2008;179(5):438-46.
27. Bowman CE. Antipsychotics for dementia: antipsychotic prescribing in care homes. BMJ 2008;337:a895.
28. Guthrie B, Clark SA, McCowan C. The burden of psychotropic drug prescribing in people with dementia: A population database study. Age Ageing 2010;39(5):637-42.
29. Bronskill SE, Anderson GM, Sykora K et al. Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. J Am Geriatr Soc 2004;52(5):749-55.
30. Larrayadieu A, Abellan van Kan G, Piau A et al. Associated factors with antipsychotic use in assisted living facilities: A cross-sectional study of 4367 residents. Age Ageing 2011;40(3):368-75.
31. Shorr RI, Fought RL, Ray WA. Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations. JAMA 1994;271(5):358-62.
32. Sanfélix-Gimeno G, Cervera-Casino P, Peiró S et al. Effectiveness of safety warnings in atypical antipsychotic drugs: an interrupted timeseries analysis in Spain. Drug Saf 2009;32(11):1075-87.
33. Thomas SK, Hodson J, McIlroy G et al. The impact of direct healthcare professional communication on prescribing practice in the UK hospital setting: an interrupted time series analysis. Drug Saf 2013;36(7):557-64.